Sick kids left in limbo by Venezuela-US crisis
When Carlos Acosta was able to fly his son out of a Venezuela that lacked basic medical supplies and see him receive a bone marrow transplant in Spain, it was as if his prayers had been answered (Source: ABC News: Health)
Source: ABC News: Health - February 23, 2019 Category: Consumer Health News Tags: Health Source Type: news
Only on AP: Sick kids left in limbo by Venezuela-US crisis
When Carlos Acosta was able to fly his son out of a Venezuela that lacked basic medical supplies and see him receive a bone marrow transplant in Spain, it was as if his prayers had been answered (Source: ABC News: Health)
Source: ABC News: Health - February 23, 2019 Category: Consumer Health News Tags: Health Source Type: news
Severely ill children left in limbo by Venezuela-US crisis
When Carlos Acosta was able to fly his son out of a Venezuela that lacked basic medical supplies and see him receive a bone marrow transplant in Spain, it was as if his prayers had been answered (Source: ABC News: Health)
Source: ABC News: Health - February 23, 2019 Category: Consumer Health News Tags: Health Source Type: news
A bioengineered factory for T-cells
(Harvard John A. Paulson School of Engineering and Applied Sciences) Harvard engineers and stem cell biologists have developed an injectable sponge-like gel that enhances the production T-cells after a bone marrow transplant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2019 Category: International Medicine & Public Health Source Type: news
A family ’s $1.6 million fight against cancer
The Jacquie Hirsch For A.L.L. Foundation works to promote awareness and testing for bone marrow transplants in the hopes of helping people with bone cancer find a match. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 7, 2019 Category: Pharmaceuticals Authors: Tracey Drury Source Type: news
Cellect Biotechnology launches U.S. clinical trial
Cellect Biotechnology (NSDQ:APOP) said it is collaborating with Washington University on a study of its ApoGraft stem cell selection technology for bone marrow transplantations.
This will be the first clinical trial in the U.S. using Tel Aviv, Israel-based Cellect’s ApoGraft, which is designed to prevent acute graft-versus-host disease following bone marrow transplantation. The company previously reported positive safety and tolerability data from an ongoing trial that is being performed outside the U.S., and expects to report additional interim results during the first half of 2019.
Get the full story on our sister ...
Source: Mass Device - February 5, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Clinical Trials News Well Oncology Regenerative Medicine cellectbiotechnology Washington University School of Medicine Source Type: news
New therapeutic target for graft-vs-host disease could make bone marrow transplant safer
(Medical University of South Carolina) Graft-versus-host disease (GVHD) is a major complication of bone marrow transplant, a potentially curative treatment for patients with blood-borne cancers such as leukemia and lymphoma. Inhibiting Sirt-1 in a mouse model helped control GVHD without making tumor relapse more likely, report researchers at the Medical University of South Carolina in Blood. The inhibitor has already been proven safe in humans but would need further testing in patients with blood-borne cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2019 Category: Cancer & Oncology Source Type: news
Addition of BMT Not Indicated in Some With Peds Hypodiploid ALL
Bone marrow transplant not beneficial if no minimal residual dz after remission induction tx (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 23, 2019 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Journal, Source Type: news
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Senior hire adds 25 years of highly relevant leadership, technical operations and supply chain experience from Pfizer and Ipsen to Actinium's Executive Team
Ms. Pussinen to lead technical and supply chain efforts to drive forward Actinium's multi-diseas... Biopharmaceuticals, Oncology, Personnel Actinium Pharmaceuticals, Iomab-B, bone marrow transplant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2019 Category: Pharmaceuticals Source Type: news
Scientists learn how common virus reactivates after transplantation
(Fred Hutchinson Cancer Research Center) A new study in Science challenges long-held theories of why a common virus -- cytomegalovirus, or CMV -- can reactivate and become a life-threatening infection in people with a compromised immune system, including blood cancer patients undergoing bone marrow transplantation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2019 Category: Cancer & Oncology Source Type: news
Young dad thanks blood donors who saved his life
As Tyler Bacon gripped the lectern in Carnesale Commons and scanned the crowd gazing at him expectantly, he struggled to hold back tears.The 39-year-old father of two from Thousand Oaks was finally meeting some of the more than two dozen people whose blood and platelet donations sustained his life during cancer treatment at Ronald Reagan UCLA Medical Center. “Because you showed up and donated, my parents still have a son,” Bacon said. “My children have a dad. My wife has a husband.”His voice quaking with emotion, he added, “All the gratitude in the world would not be enough to say thank you.”Bacon hugged ea...
Source: UCLA Newsroom: Health Sciences - January 17, 2019 Category: Universities & Medical Training Source Type: news
Father of two thanks blood donors who saved his life
As Tyler Bacon gripped the lectern in Carnesale Commons and scanned the crowd gazing at him expectantly, he struggled to hold back tears.The 39-year-old father of two from Thousand Oaks was finally meeting some of the more than two dozen people whose blood and platelet donations sustained his life during cancer treatment at Ronald Reagan UCLA Medical Center. “Because you showed up and donated, my parents still have a son,” Bacon said. “My children have a dad. My wife has a husband.”His voice quaking with emotion, he added, “All the gratitude in the world would not be enough to say thank you.”Bacon hugged ea...
Source: UCLA Newsroom: Health Sciences - January 16, 2019 Category: Universities & Medical Training Source Type: news
UCLA researchers correct genetic mutation that causes IPEX, a life-threatening autoimmune syndrome
UCLA researchers led by Dr. Donald Kohn have created a method for modifying blood stem cells to reverse the genetic mutation that causes a life-threatening autoimmune syndrome called IPEX. The gene therapy, which was tested in mice, is similar to the technique Kohn has used to cure patients with another immune disease, severe combined immune deficiency, or SCID, also known as bubble baby disease.The workis described in a study published in the journal Cell Stem Cell.IPEX is caused by a mutation that prevents a gene called FoxP3 from making a protein needed for blood stem cells to produce immune cells called regulatory T ce...
Source: UCLA Newsroom: Health Sciences - January 10, 2019 Category: Universities & Medical Training Source Type: news
Stem cell study offers clues for optimizing bone marrow transplants and more
Bone marrow transplants, which involve transplanting healthy blood stem cells, offer the best treatment for many types of cancers, blood disorders and immune diseases. Even though 22,000 of these procedures are performed each year in the US, much remains to be understood about how they work. (Source: World Pharma News)
Source: World Pharma News - January 9, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Stem cell study offers clues for optimizing bone marrow transplants and more
(University of Southern California - Health Sciences) A new USC and Stanford study, conducted in mice, shows that successfully transplanted stem cells don't behave 'normally' as in a healthy person without a transplant. Instead, the radiation and high-dose chemotherapy used to wipe out diseased stem cells prior to transplantation appear to trigger 'extreme behavior' in the newly transplanted cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 9, 2019 Category: International Medicine & Public Health Source Type: news